Taiho to acquire Merck & Co's Japanese R&D centre
This article was originally published in Scrip
Merck & Co's wholly owned Japanese subsidiary, Banyu, has agreed to sell its main R&D facility to Taiho Pharmaceutical, a mid-sized Japanese company specialising in oncology.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.